



ASX / MEDIA RELEASE

Compumedics Intensifies Its China Focus

Compumedics to Exhibit at China Medical Equipment Fair in Shenzhen — China's Largest Medical Equipment Congress

MELBOURNE, 18 April 2011: Compumedics Limited (ASX:CMP) is pleased to announce that it is exhibiting at the 2011 China Medical Equipment Fair (CMEF), commencing today. This forms part of Compumedics' corporate development and strategic alliance program.

Australia's close proximity and excellent trading relationships with China, coupled with Compumedics' well established reputation and market leadership in multiple exciting medical device growth sectors, provide a unique opportunity for Compumedics to strengthen its business and investment links with China. In particular, China is an important growth market, which augurs well as Compumedics continues to actively seek to complement its existing Chinese business with strategic alliances and investment partners. Compumedics' reputation in China as a premier supplier of sleep and neurology (Neuroscan) monitoring systems, coupled with its ongoing activity in the Chinese markets; as highlighted by the recently announced Chinese DWL Doppler blood-flow monitoring contract (ASX 23 Dec 2010), provides a strong basis to further Compumedics' Chinese relationships and ongoing business development.

Compumedics seeks to establish alliances with progressive Chinese entities or other global organizations wishing to take advantage of Compumedics' unique presence in the China and Asia Pacific region. The principal goal is to consider combining China's unsurpassed manufacturing capabilities with Compumedics' well-established reputation and rich technology and product folio, which includes over 20,000 systems installed in many of the world's finest hospitals, clinics and universities.

Importantly, Compumedics has recently commenced the roll-out of its new auto-titration range of sleep treatment products (APAP; CPAP) including the SomniLink® SPAP® system which has been clinically validated against world-leading auto-titration sleep apnoea treatment devices. The sleep apnoea treatment device market has grown from a miniscule base only two decades ago, to represent one of today's most exciting multi-billion dollar medical device markets. The combination China's industrial strengths and Compumedics innovative SomniLink® SPAP® technology potentially enables China to not only supply its own local markets with best of class Chinese manufactures auto-titration technology but to also equip the global market with the innovative SomniLink® SPAP® sleep treatment systems. These systems have been designed to not only minimise sleep disordered breathing but to maximize sleep efficiency.

Accordingly, with these goals in mind Compumedics will be attending the Shenzhen China Medical Equipment Fair (CMEF; 16-19th April 2011) as part of the Australian Government's export pavilion (Austrade) and expressions of strategic interest are being directed to:

Mr Gerald Lim (Attending CMEF);

Corporate Development/ Marketing Manager

Mobile +61 (0) 41 333 6543;

Fax : +61 (0) 3 8420 7399

Email : geraldlim@compumedics.com.au; www.compumedics.com

Or

David Burton, PhD
CEO, Chairman
Compumedics Limited
30-40 Flockhart St
Abbotsford; Vic. 3067, Australia
Email - dburton@compumedics.com

About Compumedics Ltd: Compumedics is a global, leading designer and supplier of high-tech sleep, brain, and ultrasonic blood-flow monitoring systems for sleep, neurological and other associated healthcare problems. Each of these markets is multi-billion dollar in scope, at an early phase of evolution, and with high growth expectations. Compumedics is a profitable company, uniquely positioned for imminent growth in each of these markets. Compumedics Limited was founded in **1987** by current Chairman/CEO Dr. David Burton and today is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In **1987** Compumedics established Asia Pacific's first fully computerized sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. In **1995** the company was selected to supply equipment to the US Sleep Heart Health Study, the world's largest sleep study of its kind, with over 8,000 participants scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe its products are distributed in over 50 countries. In **1998** Compumedics was awarded the overall Australian Exporter of the Year. In **2000** Compumedics was listed on the Australian Stock Exchange. In **2002**, Compumedics acquired US-based **Neuroscan** - the world's leading supplier of instruments for brain research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. In **2003** Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. In **2004**, Compumedics acquired Germany-based **DWL Elektronische GmbH**, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. In **2006**, Compumedics was awarded the Frost and Sullivan Technology Leadership award for its innovative Somté® recorder product. In **2007**, Compumedics and its Chairman were inducted into the Victorian Manufacturing Hall of Fame. In **2008** the DWL division received a top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics Compumedics sales have grown more than 4-fold from \$9 million (1999) to \$39 million (2008). In **2009** Compumedics was awarded a design award for its GRAEL® PSG/EEG premium laboratory-based product. In **2010** Compumedics was recognized by the Australian Innovation Government and Industry body as one of Australia's Top 100 Health Innovators through its' world leading devices for sleep diagnostics. **For further background please visit:** www.compumedics.com <http://www.compumedics.com>

For further information please contact:

Compumedics CEO/Chairman: Dr. David Burton 61-3-8420-7300; dburton@compumedics.com.au

Bourse Communications: Mr. Rod North T: 03 9510 8309 M: 0408 670 706 E:rod@boursecommunications.com.au

Investors: CMP.ASX (ASX.COM)

For personal use only